Which drugs cause prolonged qt

Prescribers should also use caution when prescribing concurrent drugs that reduce serum potassium. The BNF 80 September — March lists the following examples of drugs which prolong the QT interval note this list is not exhaustive , and not all drugs are included within the Devon Formulary :. The BNF 80 September — March also lists the following drugs that are predicted by the manufacturer to increase the risk of QT prolongation, and therefore concurrent use alongside drugs that prolong the QT interval should be avoided:.

Cookies Policy. Close Privacy Overview This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website.

We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience. Necessary Necessary. Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website.

These cookies do not store any personal information. Non Necessary non-necessary. The incidence of QT prolongation and TdP is well documented with the antiarrhythmic agents. Although they are beneficial for the acute termination of an arrhythmia, there has been little documentation supporting their use for chronic management of arrhythmias.

As previously mentioned, it is important to assess the nonpharmacologic risk factors Table 1 when selecting a medication that has been associated with QT prolongation. Close monitoring is particularly necessary when choosing to use QT-prolonging drugs within this population of patients at risk. Patients should be counseled about the potential risks associated with these medications and informed of the symptoms of arrhythmia. Patients should seek medical attention if symptoms such as lightheadedness, dizziness, palpitations, shortness of breath, or syncope occur.

Conclusion Although QT prolongation has been linked to the use of certain drugs, it remains difficult to predict the relative risk associated with their administration. Pharmacists can make recommendations to clinicians to help promote safer prescribing practices when selecting QT-prolonging drugs.

Drugs that have QT-prolonging effects should not exceed recommended dosing range, as drug-induced arrhythmia is often a result of high drug concentrations. In addition, these medications should be prescribed with caution in patients who have underlying risk factors, such as cardiac disorders. Screening for potential drug interactions and electrolyte abnormalities may also help lead to safer therapies, potentially preventing the development of ventricular arrhythmias. References 1.

What clinicians should know about the QT interval. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. Drug induced QT prolongation and torsades de pointes. Darpo B. Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes.

Eur Heart J Supplements. Chiang C. Drug-induced long QT syndrome. J Med Biol Eng. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin and moxifloxacin. Antimicrobial safety: focus on fluoroquinolones. Clin Infec Dis. Taylor DM. Antipsychotics and QT prolongation. Acta Psychiatr Scand. Anti-psychotic related QTc prolongation, torsades de pointes and sudden death. Taylor D. Ziprasidone in the management of schizophrenia: the QT interval issue in context.

CNS Drugs. Kupec IF. Seldane and generic terfenidine withdrawn from market. Feb 27,